Nuwellis Research and Development Expenses 2011-2024 | NUWE

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Nuwellis research and development expenses from 2011 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Nuwellis Research and Development Expenses 2011-2024 | NUWE

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Nuwellis research and development expenses from 2011 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
Thermo Fisher Scientific (TMO)	$211B
Intuitive Surgical (ISRG)	$191.1B
Alcon (ALC)	$45.7B
IQVIA Holdings (IQV)	$39.8B
Edwards Lifesciences (EW)	$39.1B
IDEXX Laboratories (IDXX)	$35.5B
DexCom (DXCM)	$27.3B
Waters (WAT)	$22.8B
SONOVA HOLDING (SONVY)	$22.1B
STERIS (STE)	$21.6B
Hologic (HOLX)	$18.3B
Sysmex ADR (SSMXY)	$12.9B
Fresenius Medical Care AG KGaA (FMS)	$12.5B
Globus Medical (GMED)	$11B
Teleflex (TFX)	$9.1B
Penumbra (PEN)	$9.1B
Masimo (MASI)	$8.7B
Glaukos (GKOS)	$7.8B
PROCEPT BioRobotics (PRCT)	$5.2B
Integer Holdings (ITGR)	$4.6B
Inari Medical (NARI)	$3B
TransMedics (TMDX)	$2.9B
LivaNova (LIVN)	$2.8B
Veracyte (VCYT)	$2.8B
Nihon Kohden (NHNKY)	$2.6B
Elekta AB (EKTAY)	$2.3B
Tandem Diabetes Care (TNDM)	$2B
Integra LifeSciences Holdings (IART)	$1.9B
RxSight (RXST)	$1.8B
Alphatec Holdings (ATEC)	$1.3B